Literature DB >> 11452933

Cytogenetic abnormalities in 42 rhabdomyosarcoma: a United Kingdom Cancer Cytogenetics Group Study.

T Gordon1, A McManus, J Anderson, T Min, J Swansbury, K Pritchard-Jones, J Shipley.   

Abstract

BACKGROUND: Rhabdomyosarcomas are the most common type of pediatric soft tissue sarcoma. The cytogenetic literature on RMS is biased towards the less common alveolar subtype (ARMS), which is frequently associated with specific translocations and the PAX3/7-FKHR fusion genes. Relatively few karyotypes are reported for the embryonal subtype (ERMS). The aim of this study was to further cytogenetic knowledge of RMS subtypes. PROCEDURE: Representative examples of all karyotypes from UKCCG; member laboratories were reexamined and their histopathologies reviewed through the United Kingdom Children's Cancer Study (Group) (UKCCSG). Molecular evidence for the PAX3/7-FKHR fusion genes was available for five ERMS and seven ARMS cases and compiled with the karyotypes.
RESULTS: Clonal chro mosome aberrations were characterized for 25 ERMS and 17 ARMS cases. Thirty-six percent of the ERMS cases involved translocation breakpoints in the 1p11-q11 region. Ten of the seventeen cases of ARMS showed cytogenetic evidence for the t(2;13)(q35;q14), consistent with molecular data available from four of these. Two further ARMS cases revealed a PAX3-FKHR and a variant PAX7-FKHR fusion gene product that were not detected cytogenetically.
CONCLUSIONS: Many of the karyotypes from both subtypes were complex. The frequent involvement of the 1p11-1q11 region and gain of chromosomes 2, 8, 12, and 13 in ERMS may be functionally significant. There was no evidence for involvement of the PAX3/7-FKHR genes in ERMS, and cryptic involvement was found in some ARMS. There were no consistent chromosomal rearrangements associated with apparently translocation negative ARMS cases.

Entities:  

Mesh:

Year:  2001        PMID: 11452933     DOI: 10.1002/1096-911X(20010201)36:2<259::AID-MPO1063>3.0.CO;2-K

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  20 in total

Review 1.  Update on childhood rhabdomyosarcoma.

Authors:  H P McDowell
Journal:  Arch Dis Child       Date:  2003-04       Impact factor: 3.791

2.  Macrophage migration inhibitory factor is secreted by rhabdomyosarcoma cells, modulates tumor metastasis by binding to CXCR4 and CXCR7 receptors and inhibits recruitment of cancer-associated fibroblasts.

Authors:  Maciej Tarnowski; Katarzyna Grymula; Rui Liu; Joanna Tarnowska; Justyna Drukala; Janina Ratajczak; Robert A Mitchell; Mariusz Z Ratajczak; Magda Kucia
Journal:  Mol Cancer Res       Date:  2010-09-22       Impact factor: 5.852

3.  Novel genes implicated in embryonal, alveolar, and pleomorphic rhabdomyosarcoma: a cytogenetic and molecular analysis of primary tumors.

Authors:  Myriam Goldstein; Isaac Meller; Josephine Issakov; Avi Orr-Urtreger
Journal:  Neoplasia       Date:  2006-05       Impact factor: 5.715

4.  Adult sclerosing rhabdomyosarcoma: cytogenetic link with embryonal rhabdomyosarcoma.

Authors:  Romaric Croes; Maria Debiec-Rychter; Kristof Cokelaere; Rita De Vos; Anne Hagemeijer; Raf Sciot
Journal:  Virchows Arch       Date:  2004-11-17       Impact factor: 4.064

5.  Molecular classification of rhabdomyosarcoma--genotypic and phenotypic determinants of diagnosis: a report from the Children's Oncology Group.

Authors:  Elai Davicioni; Michael J Anderson; Friedrich Graf Finckenstein; James C Lynch; Stephen J Qualman; Hiroyuki Shimada; Deborah E Schofield; Jonathan D Buckley; William H Meyer; Poul H B Sorensen; Timothy J Triche
Journal:  Am J Pathol       Date:  2009-01-15       Impact factor: 4.307

6.  Alterations of RB1 gene in embryonal and alveolar rhabdomyosarcoma: special reference to utility of pRB immunoreactivity in differential diagnosis of rhabdomyosarcoma subtype.

Authors:  Kenichi Kohashi; Yoshinao Oda; Hidetaka Yamamoto; Sadafumi Tamiya; Tomonari Takahira; Yukiko Takahashi; Tatsuro Tajiri; Tomoaki Taguchi; Sachiyo Suita; Masazumi Tsuneyoshi
Journal:  J Cancer Res Clin Oncol       Date:  2008-04-02       Impact factor: 4.553

Review 7.  Genomic characteristics of soft tissue sarcomas.

Authors:  Fredrik Mertens; Ioannis Panagopoulos; Nils Mandahl
Journal:  Virchows Arch       Date:  2009-02-03       Impact factor: 4.064

8.  Sorafenib inhibits tumor growth and vascularization of rhabdomyosarcoma cells by blocking IGF-1R-mediated signaling.

Authors:  Wessen Maruwge; Pádraig D'Arcy; Annika Folin; Slavica Brnjic; Johan Wejde; Anthony Davis; Fredrik Erlandsson; Jonas Bergh; Bertha Brodin
Journal:  Onco Targets Ther       Date:  2008-11-01       Impact factor: 4.147

Review 9.  Myogenin and MyoD1 expression in paediatric rhabdomyosarcomas.

Authors:  N J Sebire; M Malone
Journal:  J Clin Pathol       Date:  2003-06       Impact factor: 3.411

10.  Regulation of expression of stromal-derived factor-1 receptors: CXCR4 and CXCR7 in human rhabdomyosarcomas.

Authors:  Maciej Tarnowski; Katarzyna Grymula; Ryan Reca; Kacper Jankowski; Radoslaw Maksym; Joanna Tarnowska; Grzegorz Przybylski; Frederic G Barr; Magdalena Kucia; Mariusz Z Ratajczak
Journal:  Mol Cancer Res       Date:  2010-01-12       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.